Aktis Oncology Earnings
NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.15+0.41 (+2.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aktis Oncology earnings summary
In its most recent report on Aug 13, 2026 (Q2 2026), AKTS posted EPS of $-0.44. Revenue for the quarter was $3.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
AKTS earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 13, 2026 | — | $-0.44 | — | -3.4% |
| May 11, 2026 | — | $-0.38 | — | +4.0% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.